Jacquelyn A Hank Selected Research

dinutuximab

12/2022	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.
1/2021	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
1/2020	Irinotecan, Temozolomide, and Dinutuximab With GM-CSF in Children With Refractory or Relapsed Neuroblastoma: A Report From the Children's Oncology Group.
1/2018	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group.
1/2017	HLA-Bw4-I-80 Isoform Differentially Influences Clinical Outcome As Compared to HLA-Bw4-T-80 and HLA-A-Bw4 Isoforms in Rituximab or Dinutuximab-Based Cancer Immunotherapy.
5/2014	Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14.18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma.
1/2009	Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group.
7/2006	Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jacquelyn A Hank Research Topics

Disease

33	Neoplasms (Cancer) 01/2022 - 06/2003
24	Neuroblastoma 12/2022 - 01/2004
14	Melanoma (Melanoma, Malignant) 01/2021 - 11/2004
6	Hypotension (Low Blood Pressure) 12/2022 - 11/2004
4	Hypersensitivity (Allergy) 12/2022 - 07/2006
3	Lymphocytosis 12/2012 - 11/2004
3	Pain (Aches) 11/2010 - 07/2006
2	Fever (Fevers) 12/2022 - 01/2009
2	Neoplasm Metastasis (Metastasis) 01/2021 - 07/2004
2	Breast Neoplasms (Breast Cancer) 01/2021 - 01/2015
2	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2019 - 01/2017
2	Renal Cell Carcinoma (Grawitz Tumor) 05/2017 - 12/2016
2	Necrosis 01/2016 - 05/2011
2	Residual Neoplasm 12/2012 - 07/2009
2	Hyperbilirubinemia 11/2010 - 11/2004
2	Hypoxia (Hypoxemia) 11/2010 - 11/2004
1	Squamous Cell Carcinoma of Head and Neck 01/2021
1	Lymphoma (Lymphomas) 01/2021
1	Experimental Melanoma 01/2021
1	Lymphatic Metastasis 01/2016
1	Acute Erythroblastic Leukemia (Erythroleukemia) 01/2016
1	Hematologic Neoplasms (Hematological Malignancy) 01/2016
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2015
1	Oliguria 12/2012
1	Renal Insufficiency (Renal Failure) 12/2012
1	Ovarian Neoplasms (Ovarian Cancer) 12/2011
1	Wounds and Injuries (Trauma) 04/2011
1	Exanthema (Rash) 11/2010
1	Capillary Leak Syndrome 01/2009
1	Urticaria (Hives) 01/2009
1	Nausea 01/2009
1	Vomiting 01/2009
1	Diarrhea 01/2009

Drug/Important Bio-Agent (IBA)

22	Interleukin-2 (IL2)IBA 12/2022 - 01/2004
17	lorukafusp alfaIBA 01/2020 - 01/2004
15	Monoclonal AntibodiesIBA 01/2022 - 06/2003
8	dinutuximabIBA 12/2022 - 07/2006
8	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 12/2022 - 01/2007
8	CytokinesIBA 01/2021 - 06/2003
8	LigandsIBA 12/2019 - 12/2010
6	AntibodiesIBA 10/2020 - 07/2006
4	Proteins (Proteins, Gene)FDA Link 10/2020 - 06/2003
4	Neoplasm Antigens (Tumor Antigens)IBA 05/2017 - 12/2008
4	KIR ReceptorsIBA 12/2016 - 12/2010
3	VaccinesIBA 01/2021 - 05/2017
3	Interleukin-2 Receptors (IL 2 Receptor)IBA 12/2011 - 11/2004
3	Transaminases (Aminotransferases)IBA 11/2010 - 11/2004
2	Temozolomide (Temodar)FDA LinkGeneric 01/2020 - 11/2017
2	Irinotecan (Camptosar)FDA LinkGeneric 01/2020 - 11/2017
2	Complement System Proteins (Complement)IBA 01/2020 - 07/2014
2	Rituximab (Mabthera)FDA Link 12/2019 - 01/2017
2	HLA-Bw4 antigenIBA 12/2019 - 01/2017
2	Isotretinoin (Accutane)FDA LinkGeneric 01/2018 - 01/2017
2	Immunoglobulin G (IgG)IBA 01/2018 - 01/2016
2	IgG Receptors (Fc gamma RI)IBA 05/2017 - 01/2016
2	Immunoglobulins (Immunoglobulin)IBA 01/2016 - 01/2015
2	GlycolipidsIBA 01/2016 - 07/2014
2	AntigensIBA 01/2016 - 01/2015
2	ResveratrolIBA 11/2011 - 05/2011
2	Dopamine (Intropin)FDA LinkGeneric 11/2010 - 03/2006
1	bempegaldesleukinIBA 01/2021
1	OligodeoxyribonucleotidesIBA 01/2021
1	Tumor Biomarkers (Tumor Markers)IBA 01/2020
1	Biomarkers (Surrogate Marker)IBA 01/2020
1	RNA (Ribonucleic Acid)IBA 01/2020
1	Therapeutic UsesIBA 01/2018
1	Carboplatin (JM8)FDA LinkGeneric 11/2017
1	Ifosfamide FDA LinkGeneric 11/2017
1	Etoposide (VP 16)FDA LinkGeneric 11/2017
1	Topotecan (Hycamtin)FDA LinkGeneric 11/2017
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 11/2017
1	aldesleukin (Proleukin)FDA Link 05/2017
1	Protein Isoforms (Isoforms)IBA 01/2017
1	Interleukin-15 (Interleukin 15)IBA 01/2016
1	RhamnoseIBA 07/2014
1	CarbohydratesIBA 07/2014
1	GlycoconjugatesIBA 07/2014
1	Recombinant ProteinsIBA 08/2013
1	C-Reactive ProteinIBA 12/2012
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2012
1	Fc Receptors (Fc Receptor)IBA 01/2012
1	Epithelial Cell Adhesion MoleculeIBA 12/2011
1	Lymphocyte Function-Associated Antigen-1 (LFA-1)IBA 12/2011
1	Actins (F Actin)IBA 12/2011
1	tucotuzumab celmoleukinIBA 12/2011
1	DNA (Deoxyribonucleic Acid)IBA 11/2011
1	Peptides (Polypeptides)IBA 01/2007

Therapy/Procedure

23	Immunotherapy 12/2022 - 01/2004
18	Therapeutics 12/2022 - 01/2004
6	Radiotherapy 01/2021 - 01/2012
2	Drug Therapy (Chemotherapy) 11/2017 - 01/2012
1	Induction Chemotherapy 01/2022
1	Intravenous Injections 10/2020
1	Injections 01/2016
1	Drug Tapering 12/2012
1	Intravenous Infusions 12/2012
1	Stem Cell Transplantation 01/2012
1	Autologous Transplantation 04/2011
1	Artificial Skin 04/2011
1	Bone Marrow Transplantation (Transplantation, Bone Marrow) 01/2009